amr industry alliance
The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces.read more
We drive and measure the life-sciences industry progress to curb antimicrobial resistance in four different areas:
We are uniting efforts to reduce the development of antimicrobial resistance, invest in R&D to meet public health needs and improve access to antibiotics, vaccines and diagnostics.
In 2018, the Alliance published its first progress report that provides unique insights into the practical steps its members are taking to respond to AMR. The findings of the report illustrate both the challenges the healthcare sector faces in tackling AMR and how the industry is essential to winning this battle.
Our case studies provide snap-shots from across the life-sciences industry, share information on the tangible steps we are taking to invest in new research to develop new antibiotics and vaccines, prevent infection ,and improve appropriate use of antibiotics.
Welcome to the second issue of the Alliance Round-Up – written for more than 100 biotech, diagnostic, generic and R&D pharma companies that are members of the AMR Industry Alliance, as well as...Read more
Representing more than 100 biotechnology, diagnostics, generics and research-based pharmaceutical companies and associations, the AMR Industry Alliance is one of the largest private sector coalitions...Read more
This is the first issue of "Alliance Round-Up" written for the more than 100 biotech, diagnostic, generic and pharma companies who are members of the AMR Industry Alliance, as well as people...Read more
amr in numbers
Life-sciences at the forefront of the battle against AMR
Development of National Action Plans
from the blog
Generic antibiotics underpin recommended prescribing guidance for most infections, accounting for between 80% and 90% of prescriptions in primary healthcare worldwide. However, increasing costs and inadequate incentives for quality-assured manufacturers is feeding through into shortages of these ess...Read more view all